Repeated IPC ischemic preconditioning, RIPC, ischemic reperfusion injury, endothelial function, end-stage renal disease, flow-mediated dilation (FMD) ischemisch preconditioneren (IPC), herhaalde IPC, ischemisch reperfusie schade, endotheel functie, flow-gemedieerde dilatatie

AN EXPLORATIVE STUDY TO ASSESS THE EFFECT OF REPEATED REMOTE ISCHEMIC PRECONDITIONING ON ENDOTHELIAL FUNCTION AND INNATE IMMUNE RESPONSES IN PATIENTS WITH END-STAGE RENAL DISEASE

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON29689

Enrollment

Registered

2015-01-30

Start date

2015-02-04

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To examine the effect of daily repeated ischemic preconditioning on brachial artery endothelial function (measured as FMD% before and after IRI) during 7 days in patients with chronic kidney disease. We will recruit 20 subjects with chronic kidney disease. The presence of a patent arterio-venous fistula (for dialysis) and peripheral artery occlusive disease (stage Fontaine 3-4) are taken as exclusion criteria. Also patients with pathology of both arms (for example, sclerodermia, dystrophy, rec

Interventions

Remote RIPC: 4 cycles of ischemia of the forearm by inflating a blood pressure cuff around the upper arm at 200 mmHg during 5 minutes followed by 5 minutes of reperfusion. This procedure will be perfo

Eligibility

Inclusion criteria

Inclusion criteria: Informed consent Age > 18 years Patients with chronic kidney disease (CKD stage 4 or 5)

Exclusion criteria

Exclusion criteria: -The presence of a patent arterio-venous fistula (for dialysis) -Peripheral artery occlusive disease stage III and IV. Poor peripheral skin vascular can interfere with performance of superficial femoral artery measurements -Simultaneous participation in another interventional study -Impossibility to perform RIPC, due to pathology of both arms (for example, sclerodermia, dystrophy, recent trauma, chronic wounds)

Design outcomes

Secondary

Measure	Time frame
To examine the effect of daily repeated ischemic preconditioning arm on superficial femoral artery function (measured as FMD%) during 7 days in patients with chronic kidney disease. To examine the effect of daily repeated ischemic preconditioning on ex vivo innate immune responses	—

Primary

Measure	Time frame
Brachial artery endothelial function (measured as flow-mediated dilation)	—

Contacts

Public ContactMichiel C. Warlé

m.warle@chir.umcn.nl024-3615333

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)